2021年医局業績 | 医局業績 | 教室紹介 | 香川大学医学部泌尿器・副腎・腎移植外科

論文（邦文）

泌尿器科外科Vol.34特別号編集委員: 杉元幹史; 『2021後期研修医がおさえておきたい泌尿器疾患TOP30』医学図書出版
Ⅰエッセンシャルアイテム　尿路造影: 常森寛行; 『2021後期研修医がおさえておきたい泌尿器疾患TOP30』医学図書出版ｐ54-61
Ⅱ疾患　前立腺癌: 土肥洋一郎, 加藤琢磨, 杉元幹史; 『2021後期研修医がおさえておきたい泌尿器疾患TOP30』医学図書出版ｐ162-176
前立腺癌、副腎腫瘍: 杉元幹史; 泌尿器病理診断アトラス-臨床と病理の対話で学ぶ-総合医学社第3章1-12、第6章1-4
前立腺癌: 加藤琢磨; 泌尿器病理診断アトラス-臨床と病理の対話で学ぶ-総合医学社第3章8-12
前立腺癌、副腎腫瘍: 土肥洋一郎; 泌尿器病理診断アトラス-臨床と病理の対話で学ぶ-総合医学社第3章1-7、第6章1-4
「各論」　Ⅲ.　各種疾患における高齢者治療の実際　前立腺がん: 加藤琢磨, 杉元幹史; 『高齢者がん治療エビデンス＆プラクティス』南江堂　ｐ187-194
骨転移を有する去勢抵抗性前立腺癌患者を対象とした塩化ラジウム-223の使用成績調査探索的解析結果 －新規ＡＲシグナル阻害薬前治療薬剤数別の部分集団解析－: 髙橋俊二, 筧善行, 舛森直哉, 絹谷清剛, 細野眞, 岡山豊, 砂谷敏行, 堀尾知代, 植村天受; 泌尿器外科　(0914-6180)34巻5号 Page529-540(2021.05)
監視療法における最近の進歩: 杉元幹史; Prostate Cancer Front Line　Vol.9　NO.2　2021.February
前立がん検診と監視療法　～過剰治療を避けるために～: 杉元幹史; 腺友倶楽部　Mo-FESTA CANCER FORUM 第7号2021.2　P4-7
抗悪性腫瘍薬（ホルモン療法薬－前立腺癌）: 田岡利宜也, 筧善行; Pocket Drugs 2021　550-554
Neoadjuvantか？Adjuvant療法か？　―IO時代の至適対象・レジメの未来像―: 田岡利宜也; Genitourinary Cancer Today 2021 No.4
早期前立腺癌に対する監視療法-From the beginning to the present and the future- Active surveillance for favorable prostate cancer-From the beginning to the present and the future-: 加藤琢磨, 土肥洋一郎, 杉元幹史; 臨床泌尿器科　第75巻第7号　p465-473
M0CRPC治療における薬剤選択　―3剤をどう使い分ける？―: 加藤琢磨, 杉元幹史; 西日本泌尿器科　83巻3号　p138-143
監視療法の重要性: 加藤琢磨, 杉元幹史; Prostate Journal Vol.8 No.2　特集:日本発の臨床研究からみた前立腺癌診療　123-130
Ⅲ. 泌尿器科医が知っておくべき前立腺癌病理の話題 5. 監視療法可能なGS3+4=7症例における候補選択基準 プレシジョンメディシンを目指した前立腺癌診療〜生検、臨床病理、遺伝子検査、リキッドバイオプシー〜: 加藤琢磨, 杉元幹史; 医学図書出版p157-162
監視療法における前立腺生検 プレシジョンメディシンを目指した前立腺癌診療〜生検、臨床病理、遺伝子検査、リキッドバイオプシー〜: 土肥洋一郎, 杉元幹史; 医学図書出版p79-83
アパルタミドのエビデンス: 土肥洋一郎, 杉元幹史; 臨床泌尿器科　75巻5号 2021年4月(320-325)
治療しないという選択肢：監視療法: 土肥洋一郎, 杉元幹史; 月刊泌尿器科,14(3):295-302,2021
馬蹄腎[私の治療]: 土肥洋一郎, 杉元幹史; 日本医事新報社 2021年10月23日 P49
臨床の場面をキリトル!　泌尿器科の医療器具・医療機器・医療製品・ケア用品一挙紹介(第4回)　腹腔鏡手術中のヒトコマ(解説): 常森寛行; Uro-Lo: 泌尿器Care & Cure (2189-8545)26巻4号 Page606-607
腹部膨満感を主訴とした巨大嚢胞性褐色細胞腫の１例: 原田怜、土肥洋一郎、藤原健悟、松田伊織、伊藤文子、山﨑真理、松岡祐貴、宮内康行、加藤琢磨、田岡利宜也、常森寛行、上田修史、杉元幹史; 西日本泌尿器科 84: 66-70, 2021

論文（英文）

A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study.: Sugimoto M, Kakehi Y, Horie S, Hirao Y, Akaza H.; Jpn J Clin Oncol. 2021 Oct 26:hyab162. doi: 10.1093/jjco/hyab162. Online ahead of print.
Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review.: Tsunemori H, Sugimoto M.; Int J Urol. 2021 Nov;28(11):1086-1092.
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.: Kobayashi M, Narita S,Matsui Y,Kanda S,Hidaka Y,Abe H,Tsuzuki T, Ito K,Kojima T,Kato M, Hatakeyama S, Matsushita Y,Naito S,Shiga M,Miyake M,Muro Y,Nakanishi S,Kato Y,Shibuya T,Hayashi T,Yasumoto H, Yoshida T, Uemura M,Taoka R,Kamiyama M,Morita S,Habuchi T,Ogawa O,Nishiyama H,Kitamura H,Kobayashi T.Japan Urological Oncology Group; BJU Int. 2021 Jun 10. doi: 10.1111/bju.15510.
Intravesical Bacillus Calmette-Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies.: Miyake M, Nishimura N, Iida K, Fujii T, Nishikawa R, Teraoka S, Takenaka A, Kikuchi H, Abe T, Shinohara N, Okajima E, Shimizu T, Hori S, Tsuchiya N, Owari T, Murakami Y, Taoka R, Kobayashi T, Kojima T, Nishiyama, N, Kitamura H, Nishiyama H, Fujimoto K.; Cancers　2021 May 26;13(11):2615. doi: 10.3390/cancers13112615.
Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.: Taoka R, Tsunemori H, Matsuoka Y, Kohashiguchi K, Miura T, Tohi Y, Miyauchi Y, Kato T, Ueda N, Sugimoto M; Int J Urol. 2021. 28(7):727-732.
Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.: Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R, Matsumoto K, Numakura K, Inokuchi J, Morizane S, Yoneyama T, Matsumura Y, Abe T, Inoue M, Yamada T, Terada N, Hirao S, Uemura M, Matsushita Y, Taoka R, Kobayashi T, Kojima T, Matsui Y, Kitamura H, Nishiyama H.Japan Urological Oncology Group; BMC Cancer. 2021 Mar 11;21(1):266. doi: 10.1186/s12885-021-07966-7.
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.: Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Ogawa O, Kitamura H, Nishiyama H.Japan Urological Oncology Group; Cancer Sci. 2021 Feb;112(2):760-773. doi: 10.1111/cas.14762.
Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.: Taoka R, Kobayashi T, Hidaka Y, Abe H, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Kamiyama M, Morita S, Ogawa O, Nishiyama H, Kitamura H, Sugimoto M.Japan Urological Oncology Group; Urol Oncol. 225;S1078-1439(21)00361-6, 2021.
Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy.: Iida K, Miyake M, Murakami K, Komiyama M, Okajima E, Sazuka T, Nishiyama N, Yasumoto H, Kimura T, Ito A, Shiga K, Yamagishi A, Kikuchi H, Sugimoto M, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K.; Int J Clin Oncol. 2021 Jul 27. doi: 10.1007/s10147-021-01988-8.
Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN: Takuma Kato, Hiromi Hirama, Koji Mitsuzuka, Satoru Maruyama, Hiroshi Sasaki, Toshihiro Saito, Ryuji Matsumoto Shinichi Sakamoto, Yasuyuki Sakai, Hiroshi Fukuhara, Yukio Naya, Hiromasa Tsukino, Isao Hara, Osamu Ogawa, Katsuyoshi Hashine, Fukuta Fumimasa, Akira Yokomizo, Yoichiro Tohi, Yoshiyuki Kakehi & Mikio Sugimoto; Prostate Cancer Prostatic Dis. 2021 Jul 12. doi: 10.1038/s41391-021-00422-4
Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer: Shiota, Masaki; Terada, Naoki; Kitamura, Hiroshi; Kojima, Takahiro; Saito, Toshihiro; Yokomizo, Akira; Kohei, Naoki; Goto, Takayuki; Kawamura, Sadafumi; Hashimoto, Yasuhiro; Takahashi, Atsushi; Kimura, Takahiro; Tabata, Ken-ichi; Tomita, Ryotaro; Hashimoto, Kohei; Sakurai, Toshihiko; Shimazui, Toru; Sakamoto, Shinichi; Kamiyama, Manabu; Tanaka, Nobumichi; Mitsuzuka, Koji; Kato, Takuma; Narita, Shintaro; Yasumoto, Hiroaki; Teraoka, Shogo; Kato, Masashi; Osawa, Takahiro; Nagumo, Yoshiyuki; Matsumoto, Hiroaki; Enokida, Hideki; Sugiyama, Takayuki; Kuroiwa, Kentaro; Inoue, Takahiro; Sugimoto, Mikio; Mizowaki, Takashi; Kamoto, Toshiyuki; Nishiyama, Hiroyuki; Eto, Masatoshi; Cancer Science. 2021 Sep;112(9):3616-3626. doi: 10.1111/cas.15038. Epub 2021 Jul 10.
Transplant Prognosis in Kidney Transplant Recipients with Diabetes under Mycophenolic Acid-Focused Therapeutic Drug Monitoring.: Nakamura E, Sofue T, Kunisho Y, Onishi K, Yamaguchi K, Ibuki E, Taoka R, Ueda N, Sugimoto M, Minamino T.; JPersMed.2021Nov18;11(11):1224.doi:10.3390/jpm11111224.PMID: 34834579 Free PMC article.
Prognostication in Japanese patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy: Nishimura N, Miyake M, Iida K, Miyamoto T, Tomida R, Numakura K, Inokuchi J, Yoneyama T, Matsumura Y, Yajima S, Masuda H, Terada N, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K; Int J Urol. First published: 2021 Dec 13. doi.org/10.1111/iju.14759 PMID:34902876
Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer: Matsuoka Y, Rikiya T, Kohashiguchi K, Tohi Y, Miyauchi Y, Kato T, Tsunemori, H, Ueda N, Sugimoto M; Curr Urol. 2021 Mar; 15: 16-21
The predictive factor for pathological downgrading after prostatectomy in patients with biopsy Gleason score 4+3 or 4+4 prostate cancer.: Tohi Y, Matsuda I, Fujiwara K, Harada S, Ito A, Yamasaki M, Miyauchi Y, Matsuoka Y, Kato T, Taoka R, Tsunemori H, Ueda N, Sugimoto M.; Mol Clin Oncol. 2021 Mar;14(3):56
6p.21 translocation renal cell carcinoma in the elderly: radiological findings mimicking fat poor angiomyolipoma or papillary renal cell carcinoma.: Tohi Y, Harada S, Kuroda N, Tanaka K, Inoue K, Kadota K, Haba R, Nishiyama Y, Ueda N, Sugimoto M.; Int Cancer Conf J. 2021 May 5;10(3):233-238.
Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study.: Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Kakehi Y, Sugimoto M.; Urol Oncol. 2021 Jun 8:S1078-1439(21)00209-X.
Apalutamide-associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy.: Tohi Y, Kataoka K, Miyai Y, Kaku Y, Dainichi T, Haba R, Tsunemori H, Sugimoto M.; IJU Case Rep. 2021 Jun 27;4(5):299-302.
Incidental Bladder Cancer Found on Cystoscopy during Prostate Biopsy: Prevalence, Pathological Findings, and Oncological Outcome.: Tohi Y, Miyauchi Y, Yamasaki M, Fujiwara K, Harada S, Matsuda I, Ito A, Matsuoka Y, Kato T, Taoka R, Tsunemori H, Ueda N, Sugimoto M.; Urol Int. 2021 Aug 5:1-7.
Positive Culture Prior to Transperineal Prostate Biopsy Was Not Associated with Post-Biopsy Febrile Urinary Tract Infection Development.: Tohi Y, Fujiwara K, Harada S, Matsuda I, Ito A, Yamasaki M, Miyauchi Y, Matsuoka Y, Kato T, Taoka R, Tsunemori H, Ueda N, Sugimoto M.; Res Rep Urol. 2021 Sep 7;13:691-698.
Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study.: Tohi Y, Kato T, Nakamura M, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Hashine K, Yokomizo A, Naito H, Hara I, Kawamura N, Inoue M, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Egawa S, Kakehi Y, Sugimoto M.; Int J Clin Oncol. 2021 Oct 2. doi: 10.1007/s10147-021-02041-4.
Two cases of immunoglobulin G4-related disease diagnosed by transvaginal urethral needle biopsy.: Murata S, Inoue K, Makita N, Suzuki I, Kubota M, Tohi Y, Sugino Y, Kawakita M.; IJU Case Rep. 2021 Jun 8;4(5):282-284.
Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells: Xia Z, Rikiya T, Dage L, Yuki M, Yoichiro T, Yoshiyuki K, Mikio S.; Int J Mol Sci. 2021 Apr 15;22(8):4102.